GSK to get $1.25 bln to settle HIV drug patent row with Gilead

Feb 2 (Reuters) - Britain's GlaxoSmithKline (GSK.L) will receive $1.25 billion from Gilead Sciences (GILD.O) as part of a settlement between its HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.